Meissauer A, Kramer M D, Schirrmacher V, Brunner G
Institute for Immunology and Genetics, German Cancer Research Centre, Heidelberg.
Exp Cell Res. 1992 Apr;199(2):179-90. doi: 10.1016/0014-4827(92)90423-6.
Recently, we have shown that plasminogen activators (PAs) of both types, urokinase-type (uPA) as well as tissue-type (tPA), are involved in the in vitro invasiveness of human melanoma cells. The present study is focused on the generation and importance of cell surface-bound plasmin in this process. The human melanoma cell lines MelJuso and MeWo expressed plasminogen binding sites on the cell surface. Plasminogen binding was saturable and not species-specific, since human and bovine plasminogen bound to the cells with comparable efficiency. The activation of the proenzyme plasminogen bound on MelJuso cells, which expressed surface-associated uPA activity, occurred almost synchronously with binding to the cell surface. Removal of cell-associated uPA considerably reduced plasmin generation on these cells. In contrast, plasminogen activation on MeWo cells, which secreted tPA into the culture supernatant and which were devoid of surface-associated PA activity, was by far less effective. The efficiency of the activation process could be increased by addition of exogenous tPA. With both cell lines, plasmin generation on the cell surface was suppressed by inhibitory monoclonal antibodies specific for the respective PA type. Selective inhibition of cell surface-associated plasmin by preincubating the cells with an inhibitory monoclonal antibody or with aprotinin, as well as removal of plasmin from the cell surface, led to a significant decrease in cellular invasiveness of both cell lines into various biological substrates such as fibrin gel, the basement membrane extract Matrigel, or intact extracellular matrix. Both cell lines were able to penetrate an intact cell layer of the human keratinocyte line HaCaT, a process, which also proved to be dependent on cell-associated plasmin. In conclusion, these data provide evidence that plasminogen activation associated with the surface of human melanoma cells is catalyzed much more efficiently by cell-associated uPA (MelJuso) than by secreted tPA (MeWo). Cell-associated plasmin, which is protected from inactivation by serum inhibitors, represents the essential component of the proteolytic cascade of plasminogen activation during in vitro invasiveness of human melanoma cells.
最近,我们已经表明,两种类型的纤溶酶原激活剂(PAs),即尿激酶型(uPA)和组织型(tPA),都参与了人黑色素瘤细胞的体外侵袭。本研究聚焦于该过程中细胞表面结合型纤溶酶的产生及其重要性。人黑色素瘤细胞系MelJuso和MeWo在细胞表面表达纤溶酶原结合位点。纤溶酶原结合具有饱和性且无物种特异性,因为人和牛的纤溶酶原以相当的效率结合到细胞上。在表达表面相关uPA活性的MelJuso细胞上,结合的纤溶酶原酶原的激活几乎与细胞表面结合同步发生。去除细胞相关的uPA会显著减少这些细胞上纤溶酶的产生。相比之下,MeWo细胞将tPA分泌到培养上清液中且缺乏表面相关的PA活性,其纤溶酶原激活效率要低得多。通过添加外源性tPA可提高激活过程的效率。对于这两种细胞系,细胞表面纤溶酶的产生都被针对各自PA类型的抑制性单克隆抗体所抑制。用抑制性单克隆抗体或抑肽酶对细胞进行预孵育,以及从细胞表面去除纤溶酶,选择性抑制细胞表面相关的纤溶酶,都会导致这两种细胞系对各种生物底物(如纤维蛋白凝胶、基底膜提取物基质胶或完整的细胞外基质)的细胞侵袭性显著降低。这两种细胞系都能够穿透人角质形成细胞系HaCaT的完整细胞层,这一过程也被证明依赖于细胞相关的纤溶酶。总之,这些数据表明,与细胞相关的uPA(MelJuso)比分泌的tPA(MeWo)更有效地催化与人黑色素瘤细胞表面相关的纤溶酶原激活。细胞相关的纤溶酶受到血清抑制剂失活的保护,是人类黑色素瘤细胞体外侵袭过程中纤溶酶原激活蛋白水解级联反应的关键组成部分。